<DOC>
	<DOCNO>NCT00014105</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy treat patient recurrent glioblastoma multiforme .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) temozolomide carboplatin patient recurrent glioblastoma multiforme . II . Determine acute long-term toxic effect regimen patient . III . Determine pharmacokinetics regimen patient . IV . Determine potential either pharmacokinetic- pharmacodynamic-mediated drug interaction patient treat regimen . V. Determine objective response rate patient treat establish MTD regimen . VI . Determine time tumor progression survival patient treat regimen . OUTLINE : This dose-escalation study . Patients stratify accord prior nitrosourea-based chemotherapy ( yes v ) . Patients receive carboplatin IV 30 minute day 1 oral temozolomide daily day 1-5 . Treatment repeat every 28 day maximum 6 course absence disease progression unacceptable toxicity . Patients persistent response may continue receive temozolomide additional 6 course . Cohorts 3-6 patient receive escalate dos carboplatin temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive carboplatin temozolomide recommend phase II dose . PROJECTED ACCRUAL : A total 13-70 patient ( 3-30 phase I 10-40 phase II ) accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent glioblastoma multiforme Measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 70100 % Life expectancy : At least 15 week Hematopoietic : Granulocyte count great 1,500/mm3 Hemoglobin least 10.0 g/dL Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure require therapy Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active uncontrolled infection No psychiatric disorder would preclude study No severe concurrent disease would preclude study No frequent vomit medical condition would interfere oral medication administration ( e.g. , partial bowel obstruction ) No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent sargramostim ( GMCSF ) Chemotherapy : No prior temozolomide No prior platinumbased chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Recovered prior major surgery Other : Recovered prior therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>